Therapeutic Reversal of Chemically Induced Parkinson Disease by Converting Astrocytes into Nigral Neurons
Hao QianiD, Jing HuiD, Dongyang ZhangiD, Fan MengiD, Xuan ZhangiD, Yuanchao XueiD, Neal K. DevarajiD, Steven F. DowdyiD, William Cary MobleyiD, Don W. ClevelandiD, Xiang‐Dong FuiD
Abstract
Parkinson disease is characterized by loss of dopamine neurons in the substantia nigra. As with other neurodegenerative diseases, no disease-modifying treatments exist. While most treatment objectives aim to prevent neuronal loss or protect vulnerable neuronal circuits, an important alternative is to replace lost neurons to reconstruct disrupted circuits. Herein we report an efficient single-step conversion of isolated mouse and human astrocytes into functional neurons by depleting the RNA binding protein PTB. Applying this approach to mice with a chemically induced Parkinsons phenotype, we provide evidence that disease manifestations can be potently reversed through converting astrocytes into new substantia nigral neurons, effectively restoring dopamine levels via reestablishing the nigrostriatal dopamine pathway. We further demonstrate similar disease reversal with a therapeutically feasible approach using antisense oligonucleotides to transiently suppress PTB. These findings identify a generalizable therapeutic strategy for treating neurodegenerative disorders through replacing lost neurons in the brain.
02 /Specification & Classification
Click any tag to browse matching papers- Citations
- 2
- Organism
- Approach
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Repressing PTBP1 is incapable to convert reactive astrocytes to dopaminergic neurons in a mouse model of Parkinson's disease
Weizhao Chen, Qiongping Zheng, … Mingtao Li·eLifePeer-reviewed·May 9, 2022
- Base editing of Ptbp1 in neurons alleviates symptoms in a mouse model for Parkinson's disease
Desirée Böck, Maria Wilhelm, … Gerald Schwank·eLifePeer-reviewed·Dec 13, 2024
- Downregulating PTBP1 fails to convert astrocytes into hippocampal neurons and to alleviate symptoms in Alzheimer's mouse models
Tiantian Guo, Xinjia Pan, … Yingjun Zhao·Journal of NeurosciencePeer-reviewed·Aug 9, 2022
- GDNF receptor agonist supports dopamine neurons in vitro and protects their function in animal model of Parkinson's disease.
Arun Kumar Mahato, Juho‐Matti Renko, … Märt Saarma·bioRxiv·Feb 4, 2019
- NATO3 protects dopaminergic neurons in mouse in vivo and human in vitro Parkinson's disease models
Eva P. Valencia-Alarcón, Lou C. Duret, … Emi Nagoshi·bioRxiv·Oct 10, 2025
- Optogenetic stimulation of nigral astrocytes is neuroprotective in a 6-OHDA model of neurodegeneration.
Jessica McNeill, Ivan Trujillo‐Pisanty, … Natalina Salmaso·bioRxiv·Jul 10, 2025